Tablet Compression Optimization of Pravastatin Tablets Using Response Surface Methodology with the Box-Behnken Design

被引:0
作者
Kim, Kang Min [1 ]
机构
[1] Kyungsung Univ, Dept Pharmaceut Sci & Technol, Busan, South Korea
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2019年 / 38卷 / 11期
关键词
Box-Behnken Design; pravastatin tablets; response surface methodology; tablet compression optimization; QUALITY; FORMULATION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was done to qualitatively predict the ranges of the tableting attributes required to achieve stable tablet compression with adequate reproducibility. A Box-Behnken design of experiments (DoE) study was used to identify three factors (compression force, and press and feeder speed) in the tableting of pravastatin tablets with reduced weight and size. For a robust compression process, three factors, four responses (hardness, content uniformity, dissolution, and disintegration time), and one center (n = 3) point were listed as critical quality attributes (CQAs) and evaluated by using Design Expert software and analysis of variance. Compression force and feeder speed significantly influenced dissolution and disintegration time (P < 0.05). Press speed was important for content uniformity. These results showed that press (20 rpm) and feeder speed (17-27 rpm), and compression force (4-7.5 kN) produced the optimal reduced weight and size tablet of pravastatin. Thus, the ideal ranges of three factors of tablet compression were successfully identified.
引用
收藏
页码:2177 / 2184
页数:8
相关论文
共 16 条
[1]  
Almeida S, 2006, ARZNEIMITTELFORSCH, V56, P70
[2]  
[Anonymous], 2018, USP42NF37, P3619
[3]  
[Anonymous], ICH HARM TRIP GUID P
[4]  
FDA, 2011, QUAL DES ANDAS EX IM
[5]   A risk management ontology for Quality-by-Design based on a new development approach according GAMP 5.0 [J].
Guebitz, Brigitte ;
Schnedl, Hubert ;
Khinast, Johannes G. .
EXPERT SYSTEMS WITH APPLICATIONS, 2012, 39 (08) :7291-7301
[6]  
Guncan G, 2017, ACTA PHARM SCI, V55, P57, DOI [10.23893/1307-2080.APS.05512, DOI 10.23893/1307-2080.APS.05512]
[7]  
Jeong Y.J., 2017, J KOR DIABETES, V18, P53
[8]  
Kader M, 2016, J Excipients Food Chem, V7, P35
[9]  
Kim K.M., 2018, J LIFE SCI, V28, P472
[10]  
Kim K.M., 2018, ASIAN J PHARM CLIN R, V11, P410